Our lab operates thanks to the support of:
- The Cole Foundation
2016 – 2019: The Cole Foundation Transition Grant
Determining the influential role of DNA repair factors in the development of B-cell lymphoma - Jewish General Hospital
2016 – 2018
Sir Mortimer B. Davis Start-Up Fund-Jewish General Hospital - Canadian Foundation for Innovation (CFI)
2016: CFI Leader Opportunity Fund Grant - Cancer Research Society (CRS)
2016 – 2018: CRS Operating Grant
Identification of novel targets for the treatment of Diffuse Large B-cell lymphoma - Canadian Institute of Health Research (CIHR)
2016-2021: CIHR Operating Grant
From genetic diversity to genomic instability: in vivo characterization of the deubiquitinase OTUB1 in B-cells - Natural Sciences and Engineering Research Council of Canada (NSERC)
2016: NSERC Research Tools and Instrument Grant
X-ray irradiator for cells and small animals - Canada Research Chairs (CRC)
2016 – 2021: CRC Tier 2 in Genome Stability and Hematological malignancies - Canadian Institute of Health Research (CIHR)
2017 – 2022: CIHR Operating Grant
Regulation of DNA double-strand break repair pathways in multiple myeloma - The Leukemia and Lymphoma Society of Canada (LLSC)
2018 – 2020: LLSC Operating Grant
Uncovering novel chemo-resistance driver mutations in Burkitt's Lymphoma